CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8,411 enrolled
Drug / intervention
mRNA-1010 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05827978
NCT05827978Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Stratified, Observer-Blind, Active-Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older

ModernaTX, Inc.·interventional·Posted Apr 25, 2023·Updated Jul 10, 2025

In Brief

A Phase 3 clinical trial evaluating mRNA-1010 and Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine for Seasonal Influenza. Completed, enrolled 8,411 participants across 103 sites.

Detailed Summary

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedApr 25, 2023
Enrollment StartApr 17, 2023
Primary CompletionJun 24, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.2 years ago

Interventions

mRNA-1010biological

Sterile liquid for injection

Licensed Quadrivalent Inactivated Seasonal Influenza Vaccinebiological

Sterile suspension for injection